AI is going to be a key enabler in our future roadmap

In an interaction with Express Healthcare, Guruswamy K, CEO, BPL Medical Technologies, shares how the company is balancing its rich legacy of innovation with a future-focused approach driven by R&D, AI integration, and digital health solutions

- 

BPL is a household name in India, especially remembered for introducing the country's first in-house ECG machine back in 1967. How do you balance this legacy while staying relevant in today's fast-evolving MedTech landscape?

Introducing India's first indigenous ECG machine in 1967 was a defining milestone and continues to inspire us. For us at BPL MedTech, legacy is not just about looking back but about building forward. We leverage the trust and credibility built over decades while staying agile and future-ready through continuous R&D, new product introductions, and digital health innovations. This balance between heritage and innovation is what keeps us relevant in today's rapidly evolving MedTech ecosystem.

BPL Medical Technologies just completed 12 years in its current form. What would you highlight as the company's biggest inflection point in this journey so far?

Since 2013, BPL Medical Technologies has grown steadily, but the true inflection point came when we strengthened our R&D and manufacturing base in India. The decision to design and produce “Made in India” solutions at scale was transformative. It positioned us as a credible domestic leader while opening new opportunities in exports and partnerships, helping us accelerate growth.

You've doubled down on “Made in India” products at a time when the government is pushing the PLI scheme. Can you share specific areas where BPL has gained a competitive edge through local manufacturing?